Latest Tax Incentives News

Prescient Therapeutics has secured FDA clearance for its PTX-100 Phase 2 trial targeting relapsed/refractory cutaneous T-cell lymphoma, while also appointing James McDonnell as its new CEO. The company reports steady progress in its cell therapy platforms and maintains a solid cash position bolstered by a recent R&D tax rebate.

Mindax Limited progresses its Mid-West Shared Infrastructure Project and seeks development partners for the Mt Forrest Iron Project, while securing a significant R&D tax incentive refund.

WIN Metals reports robust drilling results at its Butchers Creek and Golden Crown projects, confirming significant resource growth potential, alongside completing a key acquisition and securing fresh capital.

Emyria Limited reports strong progress in its MDMA and psilocybin-assisted therapy programs alongside a successful $2.525 million capital raise, positioning the company for expanded mental health treatment services.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Blue Energy Limited reports steady progress in its Sapphire Pilot gas production despite operational interruptions and ongoing environmental authority appeals, while advancing seismic exploration in the Northern Territory.

Papyrus Australia has taken significant strides in Q4 2024, signing a joint venture terms sheet in Vietnam, appointing new board members, and securing R&D tax incentives, positioning itself for expanded commercialization.

Papyrus Australia Ltd reported a $284,000 net cash outflow for the December 2024 quarter, reflecting abnormal expenses but maintaining a solid funding runway through existing facilities and strategic initiatives.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.

Andromeda Metals has made significant strides in advancing its Great White Project, progressing funding efforts for Stage 1A+ and securing key operational milestones. The company also bolstered its leadership with new board appointments and received a substantial tax refund, positioning it for a critical investment decision.